Organon Drug Patent Portfolio
Organon owns 12 orange book drugs protected by 53 US patents with Implanon having the least patent protection, holding only 1 patent. And Clarinex with maximum patent protection, holding 14 patents. Given below is the complete list of Organon's drugs and the patents protecting them.
1. Clarinex
Clarinex is protected by 14 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(3 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(3 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(4 years ago)
| Expired |
| US7405223
(Pediatric)
| Treating allergic and inflammatory conditions |
07 Jan, 2020
(4 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(5 years ago)
| Expired |
| US7405223 | Treating allergic and inflammatory conditions |
07 Jul, 2019
(5 years ago)
| Expired |
| US5607697
(Pediatric)
| Taste masking microparticles for oral dosage forms |
07 Dec, 2015
(8 years ago)
| Expired |
| US7211582
(Pediatric)
| Methods for treating urticaria using descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(9 years ago)
| Expired |
| US5607697 | Taste masking microparticles for oral dosage forms |
07 Jun, 2015
(9 years ago)
| Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine |
30 Dec, 2014
(9 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(9 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex's drug page
2. Clarinex D 24 Hour
Clarinex D 24 Hour is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7820199
(Pediatric)
| Stable extended release oral dosage composition |
28 Sep, 2022
(1 year, 11 months ago)
| Expired |
| US6979463 | Stable extended release oral dosage composition |
28 Mar, 2022
(2 years ago)
| Expired |
| US7820199 | Stable extended release oral dosage composition |
28 Mar, 2022
(2 years ago)
| Expired |
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(3 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(3 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(4 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(5 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(9 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex D 24 Hour's drug page
3. Fosamax
Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5358941
(Pediatric)
| Dry mix formulation for bisphosphonic acids with lactose |
02 Jun, 2013
(11 years ago)
| Expired |
| US5681590
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(11 years ago)
| Expired |
| US6090410
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(11 years ago)
| Expired |
| US6194004
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(11 years ago)
| Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose |
02 Dec, 2012
(11 years ago)
| Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(11 years ago)
| Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(11 years ago)
| Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page
4. Implanon
Implanon is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant |
28 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Implanon's drug page
5. Liptruzet
Liptruzet is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| US5969156
(Pediatric)
| Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jan, 2017
(7 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(7 years ago)
| Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jul, 2016
(8 years ago)
| Expired |
| US5686104
(Pediatric)
| Stable oral CI-981 formulation and process of preparing same |
11 May, 2015
(9 years ago)
| Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same |
11 Nov, 2014
(9 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(10 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Liptruzet's drug page
Explore Our Curated Drug Screens
6. Maxalt-mlt
Maxalt-mlt is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5457895
(Pediatric)
| Method of identifying freeze-dried dosage forms |
01 Apr, 2014
(10 years ago)
| Expired |
| US5457895 | Method of identifying freeze-dried dosage forms |
01 Oct, 2013
(10 years ago)
| Expired |
| US5298520
(Pediatric)
| Triazole containing indole derivatives |
29 Dec, 2012
(11 years ago)
| Expired |
| US5602162
(Pediatric)
| Imidazole, triazole and tetrazole derivatives |
28 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Maxalt-mlt's drug page
7. Nexplanon
Nexplanon is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant |
28 Jul, 2030
(5 years from now)
| Active |
| US8722037 | X-ray visible drug delivery device |
28 Sep, 2027
(3 years from now)
| Active |
| US10821277 | Kit for and method of assembling an applicator for inserting an implant |
31 May, 2027
(2 years from now)
| Active |
| US8888745 | Applicator for inserting an implant |
28 Aug, 2026
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexplanon's drug page
8. Propecia
Propecia is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5571817 | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
05 Nov, 2013
(10 years ago)
| Expired |
| US5547957 | Method of treating androgenic alopecia with 5-α reductase inhibitors |
15 Oct, 2013
(10 years ago)
| Expired |
| US5886184 | Finasteride processes |
19 Nov, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Propecia's drug page
9. Proscar
Proscar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5942519 | Prevention of precipitated acute urinary retention |
23 Oct, 2018
(5 years ago)
| Expired |
| US5886184 | Finasteride processes |
19 Nov, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Proscar's drug page
10. Singulair
Singulair is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8007830 | Granule formation |
24 Oct, 2022
(1 year, 10 months ago)
| Expired |
| US5565473
(Pediatric)
| Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
03 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Singulair's drug page
11. Vytorin
Vytorin is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE37721
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(7 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(7 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(10 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vytorin's drug page
12. Zetia
Zetia is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612058
(Pediatric)
| Methods for inhibiting sterol absorption |
30 Apr, 2026
(1 year, 7 months from now)
| Active |
| US7612058 | Methods for inhibiting sterol absorption |
30 Oct, 2025
(1 year, 1 month from now)
| Active |
| US7030106
(Pediatric)
| Sterol absorption inhibitor compositions |
25 Jul, 2022
(2 years ago)
| Expired |
| US7030106 | Sterol absorption inhibitor compositions |
25 Jan, 2022
(2 years ago)
| Expired |
| USRE37721
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(7 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(7 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(10 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zetia's drug page